Collaborative Arrangements and Licensing Agreements, Satellite Company Collaborations - Achaogen, Inc. (Details)	1 Months Ended	3 Months Ended								12 Months Ended
	Sep. 30, 2014 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) Drug	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2006 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		$ 51,571,000	$ 49,121,000	$ 120,428,000	$ 62,583,000	$ 84,861,000	$ 44,063,000	$ 57,076,000	$ 28,161,000	$ 283,703,000	$ 214,161,000	$ 147,285,000
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Cumulative payments and/or fees received		7,000,000								$ 7,000,000
Milestone payment earned	$ 4,000,000
Number of drugs to be developed and commercialized | Drug										2
Next potential milestone		7,500,000								$ 7,500,000
Revenue earned										0	4,000,000	$ 0
Net proceeds from sale of stock											$ 1,300,000
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Pre Specified Events [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		$ 49,300,000								$ 49,300,000
Achaogen Inc [Member] | Satellite Company Collaboration and Licensing Agreement [Member] | Series A preferred stock [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee in the form of equity securities													$ 1,500,000